Intuitive Surgical (NASDAQ:ISRG) Trading Up 0.4% – Should You Buy?

Intuitive Surgical, Inc. (NASDAQ:ISRG)’s stock price rose 0.4% during mid-day trading on Thursday . The stock traded as high as $591.58 and last traded at $592.06. Approximately 237,785 shares changed hands during trading, a decline of 86% from the average daily volume of 1,737,968 shares. The stock had previously closed at $589.61.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a report on Friday, October 18th. Bernstein Bank raised their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, BTIG Research raised their price objective on Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Stock Up 0.7 %

The company’s 50 day simple moving average is $559.48 and its 200-day simple moving average is $519.06. The firm has a market cap of $212.12 billion, a P/E ratio of 92.91, a P/E/G ratio of 5.67 and a beta of 1.39.

Insider Buying and Selling

In related news, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. This trade represents a 27.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,348 shares of company stock valued at $3,587,582. Insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Atala Financial Inc acquired a new stake in Intuitive Surgical during the 4th quarter worth about $25,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth about $26,000. Parvin Asset Management LLC acquired a new position in Intuitive Surgical in the 4th quarter worth approximately $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $28,000. Finally, Hurley Capital LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $28,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.